8-Jun-2026
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Globe Newswire (Mon, 8-Jun 9:01 AM ET)
Iovance rises as Australia approves melanoma therapy Amtagvi
Seeking Alpha News (Thu, 4-Jun 12:27 PM ET)
TipRanks (Thu, 4-Jun 6:15 AM ET)
Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
TipRanks (Thu, 4-Jun 4:25 AM ET)
Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Globe Newswire (Wed, 3-Jun 4:05 PM ET)
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Globe Newswire (Mon, 1-Jun 8:30 AM ET)
Globe Newswire (Mon, 1-Jun 7:30 AM ET)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Fri, 22-May 5:15 PM ET)
Iovance Biotherapeutics to Present at Upcoming Conference
Globe Newswire (Thu, 21-May 8:05 AM ET)
Globe Newswire (Thu, 7-May 7:05 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of June 8, 2026, IOVA stock price declined to $4.00 with 10,718,226 million shares trading.
IOVA has a beta of 0.85, meaning it tends to be less sensitive to market movements. IOVA has a correlation of 0.01 to the broad based SPY ETF.
IOVA has a market cap of $1.79 billion. This is considered a Small Cap stock.
Last quarter Iovance Biotherapeutics reported $71 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.03.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
IOVA has outperformed the market in the last year with a return of +95.1%, while the SPY ETF gained +24.6%. However, in the most recent history, IOVA shares have underperformed the stock market with its stock returning -22.0% in the last 3 month period and -2.7% for the last 2 week period, while SPY has returned +10.2% and -0.9%, respectively.
IOVA support price is $3.98 and resistance is $4.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.